Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with mRCC.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e16539
Abstract: e16539Background: Checkpoint inhibitors (CPIs) are a treatment option for patients with metastatic renal cell carcinoma (mRCC), but there is limited clinical data on the efficacy of targeted therap... read more here.
Keywords: treatment; versus tkis; cpi treatment; treatment real ... See more keywords